# Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer

> **NCT00003041** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pyrazoloacridine

## Key facts

- **NCT ID:** NCT00003041
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07
- **Primary completion:** —
- **Final completion:** 2002-01
- **Target enrollment:** — (—)
- **Last updated:** 2013-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003041, "Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00003041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*